Recovery From Disability: Manual of Psychiatric RehabilitationJune 9th 2011
Given Dr Liberman’s remarkable productivity and his amazing capacity to keep his finger on the pulse of the field, I expect to find practical guidance in such circumstances in the next edition of Recovery From Disability.
The 2011 Psychiatric Times Ethics Survey: Moral StrugglesJune 8th 2011
The goal of the survey was to go beyond ethical lessons, useful as these may be, and to learn how Psychiatric Times’ readers-who are on the front line of psychiatric practice-handle a series of hypothetical ethical scenarios.
A Psychiatrist’s Perspective on a Potentially Explosive IssueJune 3rd 2011
Had the National Rifle Association (NRA) had its way and Bill 432 had been voted into law in Florida, physicians in that state would have been prohibited from asking their patients whether they have access to firearms.
What’s in It for Psychiatrists?June 2nd 2011
The challenge to learn enough relevant information about a patient in brief medication (and evaluative) sessions still exists. And there is also the challenge of picking a medication that will be acceptable and valued-both from a symbolic and biological standpoint.
Black Psychiatrists of America Speak About Desmond TutuJune 2nd 2011
On behalf of the Black Psychiatrists of America, we are writing to the American Psychiatric Association regarding the recent “issues” that have been raised by some members of your association with respect to Archbishop Tutu being this year’s convocation speaker at your annual meeting in Hawaii in May.
Ethical Issues in PsychopharmacologyMay 7th 2011
Excellence in psychopharmacology demands sensitivity to the associated ethical considerations. The key considerations of psychiatry are both complex and dynamic, and psychiatrists who develop and refine their ethics skill set will be in a better position to anticipate and respond to ethical dilemmas as they arise in their practice.
Does MDMA Have a Role in Clinical Psychiatry?May 7th 2011
Like every drug or technology that has therapeutic value, MDMA (3,4-methylenedioxymethamphetamine) has potential risks and benefits. Unlike most other drugs under clinical investigation, MDMA has a complex and controversial history that has delayed dispassionate scientific investigation into its therapeutic use.